



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Cinpanemab

Cat. No.:	HY-P99356
CAS No.:	2094516-02-4
Target:	$\alpha$ -synuclein
Pathway:	Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Cinpanemab (BIB054) is a human-derived monoclonal antibody that binds to $\alpha$ -synuclein. Cinpanemab can be used for the research of Parkinson's disease <sup>[1][2]</sup> .	
<b>IC<sub>50</sub> &amp; Target</b>	$\alpha$ -synuclein <sup>[1]</sup>	
<b>In Vitro</b>	Cinpanemab is highly selective for aggregated forms of $\alpha$ -syn with at least an 800-fold higher apparent affinity for fibrillar versus monomeric recombinant $\alpha$ -syn and a strong preference for human PD brain tissue <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
<b>In Vivo</b>	Cinpanemab (30 mg/kg; i.p.) improves PD-like phenotypes in $\alpha$ -syn PFF inoculation mouse models <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	<b>Animal Model:</b>	C57BL/6JRcHsd WT mice, transgenic M83 mice expressing human $\alpha$ -syn A53T, and transgenic bacterial artificial chromosome mice expressing human $\alpha$ -syn A53T were anesthetized and stereotaxically injected with $\alpha$ -syn preformed fibrils (PFFs) into the right forebrain <sup>[2]</sup>
	<b>Dosage:</b>	30 mg/kg
	<b>Administration:</b>	Intraperitoneal (i.p.) injections 2-3 times prior to $\alpha$ -syn PFF injection and weekly post-injection until time of sacrifice
	<b>Result:</b>	Attenuated the spreading of $\alpha$ -syn pathology, rescued motor impairments, and reduced the loss of dopamine transporter density in dopaminergic terminals in striatum.

### REFERENCES

[1]. Lang AE, et, al. Trial of Cinpanemab in Early Parkinson's Disease. N Engl J Med. 2022 Aug 4;387(5):408-420.

[2]. Teng JS, et, al. Immunotherapies for Parkinson's Disease: Progression of Clinical Development. CNS Neurol Disord Drug Targets. 2021;20(9):802-813.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA